

Engineering B cells to produce protective antibodies

Session: What is coming next for *in vivo* gene therapy?

Justin J. Taylor PhD

Associate Professor

Immunology and Vaccine Development Program

Vaccine and Infectious Disease Division



FRED HUTCH CURES START HERE®





IAS 2021 18 – 21 July

Summary FOR COMMUNITY

• Key question:

Can we replace non-protective antibodies in immune cells with antibodies protective against HIV?


Why is this important and related to cure?

Engineered immune cells could represent a *single injection* that would provide a life-long source of antibodies able to control HIV.






Engineering to mimic a protective antibody response



Created using BioRender.com




Results: Highly efficient engineering of human B cells




Created using BioRender.com

Howell Moffett PhD Carson Harms MS Marti Tooley





Results: Engineered mouse B cells (an protect against a viral infection)



SCIENCE IMMUNOLOGY | RESEARCH ARTICLE 2019


B cells engineered to express pathogen-specific antibodies protect against infection

Howell F. Moffett¹, Carson K. Harms¹, Kristin S. Fitzpatrick¹, Marti R. Tooley¹, Jim Boonyaratanakornkit¹, Justin J. Taylor^{1,2,3}*



Created using BioRender.com

Long-term goal: In vivo engineering



Key Properties

Efficiency and durability

Multiple Antibodies

Safety: Off-target & mispairing



Created using BioRender.com



Disclosures and Acknowledgements



jtaylor3@fredhutch.org

Engineering Team

Jim Boonyaratanakornkit MD PhD Kristin Fitzpatrick (UW PhD Student) Jessica Schembri MS Matt Gray PhD Molly Kanagy Kay Hopwo Julia Luna McKechnie PhD

Howell Moffett PhD (Outpace Bio) Carson Harms MS (Lyell Immunopharma) Marti Tooley (UW PhD Student) Erica Naibert (Umoja Biopharma)



FRED HUTCH CURES START HERE®

Key Collaborators

Jen Adair PhD & Lab Hans-Peter Kiem MD PhD & Lab

NIR

THE HARTWELL FOUNDATION



